Fc修饰HIV-1单抗VRC01LS的1期安全性与药代动力学
VRC01LS是靶向HIV-1 Env CD4结合位点的Fc修饰广谱中和单抗,在HIV阴性健康成人中开展1期开放标签剂量递增试验,评估静脉5、20、40 mg/kg及皮下5 mg/kg给药的安全性与药代动力学。未发生严重不良事件或剂量限制性毒性,半衰期较野生型VRC01历史数据延长超过4倍。
要点
- VRC01LS静脉或皮下给药在HIV阴性健康成人中安全且耐受良好,无严重不良事件或剂量限制性毒性。
- 单次静脉20或40 mg/kg后12周平均血清浓度分别为180±43 μg/mL(n=7)和326±35 μg/mL(n=5)。
- 5–40 mg/kg静脉剂量范围内清除率36±8 mL/d,消除半衰期71±18天,较野生型VRC01历史数据延长超过4倍。
核心结论
- VRC01LS静脉或皮下给药在HIV阴性健康成人中安全且耐受良好,半衰期较野生型VRC01历史数据延长超过4倍。
- 清除率降低和半衰期延长可能使以更低剂量和更少频次给药达到治疗水平成为可能。
研究设计与样本
- 1期开放标签剂量递增研究,由美国NIH疫苗研究中心(VRC)在NIH临床中心开展。
- 研究对象为21–50岁HIV阴性健康成人,男性51%、女性49%。
- 静脉给药5、20、40 mg/kg单次及20 mg/kg每12周三次,皮下给药5 mg/kg单次及每12周三次。
- 本报告描述首批37名接受VRC01LS给药志愿者的安全性数据;药代动力学基于前25名完成评估计划志愿者首剂数据建模。
主要发现
- 无严重不良事件(SAE)或剂量限制性毒性;轻度不适和肌痛为最常见不良事件。
- 6例不良事件被评估为可能与VRC01LS给药相关,均为轻度并在研究期间缓解。
- 单次静脉20 mg/kg或40 mg/kg后12周平均(±SD)血清浓度分别为180±43 μg/mL(n=7)和326±35 μg/mL(n=5)。
- 单次静脉与皮下5 mg/kg后12周平均(±SD)血清浓度分别为40±3 μg/mL(n=2)和25±5 μg/mL(n=9)。
- 5–40 mg/kg静脉剂量范围内(n=16)清除率36±8 mL/d,消除半衰期71±18天;血清中和活性保留,未检测到抗VRC01抗体应答。
关键数值与推荐
- 静脉给药剂量:5、20、40 mg/kg单次;20 mg/kg每12周一次共三次。
- 皮下给药剂量:5 mg/kg单次或每12周一次共三次。
- 5–40 mg/kg静脉剂量范围(n=16)清除率36±8 mL/d,消除半衰期71±18天。
临床怎么用
- VRC01LS静脉或皮下给药在HIV阴性健康成人中安全且耐受良好。
- 清除率降低和半衰期延长可能使以更低剂量和更少频次给药达到治疗水平成为可能,并可能降低制造成本、提高被动给予单抗用于HIV-1预防的可行性。
局限性
- 样本量小,为1期试验的典型特征。
- 需进一步描述VRC01LS多次给药后的药代动力学特性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being evaluated in a Phase IIb adult HIV-1 prevention efficacy trial. VRC01LS is a modified version of VRC01, designed for extended serum half-life by increased binding affinity to the neonatal Fc receptor. METHODS AND FINDINGS: This Phase I dose-escalation study of VRC01LS in HIV-negative healthy adults was conducted by the Vaccine Research Center (VRC) at the National Institutes of Health (NIH) Clinical Center (Bethesda, MD). The age range of the study volunteers was 21-50 years; 51% of study volunteers were male and 49% were female. Primary objectives were safety and tolerability of VRC01LS intravenous (IV) infusions at 5, 20, and 40 mg/kg infused once, 20 mg/kg given three times at 12-week intervals, and subcutaneous (SC) delivery at 5 mg/kg delivered once, or three times at 12-week intervals. Secondary objectives were pharmacokinetics (PK), serum neutralization activity, and development of antidrug antibodies. Enrollment began on November 16, 2015, and concluded on August 23, 2017. This report describes the safety data for the first 37 volunteers who received administrations of VRC01LS. There were no serious adverse events (SAEs) or dose-limiting toxicities. Mild malaise and myalgia were the most common adverse events (AEs). There were six AEs assessed as possibly related to VRC01LS administration, and all were mild in severity and resolved during the study. PK data were modeled based on the first dose of VRC01LS in the first 25 volunteers to complete their schedule of evaluations. The mean (±SD) serum concentration 12 weeks after one IV administration of 20 mg/kg or 40 mg/kg were 180 ± 43 μg/mL (n = 7) and 326 ± 35 μg/mL (n = 5), respectively. The mean (±SD) serum concentration 12 weeks after one IV and SC administration of 5 mg/kg were 40 ± 3 μg/mL (n = 2) and 25 ± 5 μg/mL (n = 9), respectively. Over the 5-40 mg/kg IV dose range (n = 16), the clearance was 36 ± 8 mL/d with an elimination half-life of 71 ± 18 days. VRC01LS retained its expected neutralizing activity in serum, and anti-VRC01 antibody responses were not detected. Potential limitations of this study include the small sample size typical of Phase I trials and the need to further describe the PK properties of VRC01LS administered on multiple occasions. CONCLUSIONS: The human bnMAb VRC01LS was safe and well tolerated when delivered intravenously or subcutaneously. The half-life was more than 4-fold greater when compared to wild-type VRC01 historical data. The reduced clearance and extended half-life may make it possible to achieve therapeutic levels with less frequent and lower-dose administrations. This would potentially lower the costs of manufacturing and improve the practicality of using passively administered monoclonal antibodies (mAbs) for the prevention of HIV-1 infection. TRIAL REGISTRATION: ClinicalTrials.gov NCT02599896.
引用
- Gaudinski MR, Coates EE, Houser KV, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018. PMID: 29364886. doi:10.1371/journal.pmed.1002493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。